Cetuximab (anti-EGFR) a novel molecular-targeted agentis an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation.

[accordions]
[accordion title= “Targets&IC50“]

EGFR:0.147 nM (Kd, Fixed A431 cells) , Soluble EGFR:0.201 nM (Kd)

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. Huang S M , Bock J M , Harari P M . Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck1[J]. Cancer Res, 1999, 59(8):1935-1940.2. H, Gustafsso, A, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model[J]. Cell Biochemistry & Biophysics, 2017.

[/accordion]